{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:44Z","timestamp":1793155724927,"version":"4.5.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Identification of appropriate patients for treatment of vasomotor symptoms (VMS) with menopausal hormone therapy (HT) is challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess risk of cardiovascular disease (CVD) due to HT in women with VMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>In this secondary analysis of 2 randomized clinical trials of HT, postmenopausal women aged 50 to 79 years from 40 US clinical centers were included. Data were collected from November 1993 to September 2012, and data were analyzed from December 2024 to May 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Conjugated equine estrogens (CEE), 0.625 mg per day, or CEE with medroxyprogesterone acetate (MPA), 2.5 mg per day, vs placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Atherosclerotic CVD (ASCVD; defined as composite of nonfatal myocardial infarction, hospitalization for angina, coronary revascularization, ischemic stroke, peripheral arterial disease, carotid artery disease, or CVD death).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 27\u202f347 included postmenopausal women, the mean (SD) age was 63.4 (7.2) years; a total of 10\u202f739 (39.3%) had a hysterectomy, and 16\u202f608 (60.7%) had an intact uterus. The median (IQR) follow-up was 7.2 (6.4-8.1) years and 5.6 (4.8-6.5) years for those in the CEE alone trial and the CEE plus MPA trial, respectively. In the CEE alone trial, moderate or severe VMS were present at baseline in 905 (27.6%), 705 (14.7%), and 220 (8.7%) women aged 50 to 59 years, 60 to 69 years, and 70 to 79 years, respectively; in the CEE plus MPA trial, moderate or severe VMS was present in 1225 (22.4%), 649 (8.7%), and 172 (4.8%), respectively. Among women with moderate or severe VMS at enrollment, 3382 (96.7%) recalled having symptoms near menopause onset. CEE alone reduced VMS by 41% across all age groups (overall relative risk [RR], 0.59; 95% CI, 0.53-0.66). However, in the CEE plus MPA trial, VMS reduction was attenuated with age (age 50-59 years: RR, 0.41; 95% CI, 0.35-0.48; age 60-69 years: RR, 0.72; 95% CI, 0.61-0.85; age 70-79 years: RR, 1.20; 95% CI, 0.91-1.59; interaction\n                      <jats:italic>P<\/jats:italic>\n                      for trend\u2009&amp;amp;lt;\u2009.001). Both CEE alone and CEE plus MPA appeared to have neutral effects on ASCVD in women with moderate or severe VMS aged 50 to 59 years (CEE alone: hazard ratio [HR], 0.85; 95% CI, 0.53-1.35; CEE plus MPA: HR, 0.84; 95% CI, 0.44-1.57). While the estimated risk was higher for CEE alone in women with VMS aged 60 to 69 years, there was no clear signal of harm (CEE alone: HR, 1.31; 95% CI, 0.90-1.90; CEE plus MPA: HR, 0.84; 95% CI, 0.51-1.39). However, women with VMS 70 years and older had increased risks of ASCVD (CEE alone: HR, 1.95; 95% CI, 1.06-3.59; 217 excess events per 10\u202f000 person-years; interaction\n                      <jats:italic>P<\/jats:italic>\n                      for trend\u2009=\u2009.03; CEE plus MPA: HR, 3.22; 95% CI, 1.36-7.63; 382 excess events per 10\u202f000 person-years; interaction\n                      <jats:italic>P<\/jats:italic>\n                      for trend\u2009=\u2009.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this secondary analysis of 2 randomized clinical trials, among younger postmenopausal women aged 50 to 59 years, both CEE alone and CEE plus MPA reduced VMS without significantly affecting ASCVD risk. In women with VMS 70 years and older, risks for ASCVD were increased in both trials. The findings support guideline recommendations for treatment of VMS with HT in women aged 50 to 59 years, caution if initiating HT in women aged 60 to 69 years, and avoidance of HT in women 70 years and older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT00000611\">NCT00000611<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.4510","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:01:08Z","timestamp":1757948468000},"page":"1330","source":"Crossref","is-referenced-by-count":43,"title":["Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms"],"prefix":"10.1001","volume":"185","author":[{"given":"Jacques E.","family":"Rossouw","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron K.","family":"Aragaki","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn E.","family":"Manson","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Szmuilowicz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Allison","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haring","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Saarland University, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazmus","family":"Saquib","sequence":"additional","affiliation":[{"name":"College of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aladdin H.","family":"Shadyab","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health and Human Longevity Science and Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Rexrode","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Drexel University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"Mouton","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Texas Medical Branch, Galveston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Z.","family":"LaCroix","sequence":"additional","affiliation":[{"name":"Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"ioi250058r1","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1097\/GME.0000000000001230","article-title":"Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women.","volume":"25","author":"Huang","year":"2018","journal-title":"Menopause"},{"issue":"13","key":"ioi250058r2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"issue":"13","key":"ioi250058r3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials.","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"ioi250058r4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0197-2456(97)00078-0","article-title":"Design of the Women\u2019s Health Initiative clinical trial and observational study.","volume":"19","author":"Anderson","year":"1998","journal-title":"Control Clin Trials"},{"issue":"1","key":"ioi250058r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40695-021-00071-6","article-title":"Taking action to advance the study of race and ethnicity: the Women\u2019s Health Initiative (WHI).","volume":"8","author":"Garcia","year":"2022","journal-title":"Womens Midlife Health"},{"issue":"3","key":"ioi250058r7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"14","key":"ioi250058r8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"ioi250058r9","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1161\/CIR.0000000000000677","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"ioi250058r10","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/S1047-2797(03)00048-6","article-title":"Outcomes ascertainment and adjudication methods in the Women\u2019s Health Initiative.","volume":"13","author":"Curb","year":"2003","journal-title":"Ann Epidemiol"},{"issue":"10","key":"ioi250058r11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.7326\/0003-4819-154-10-201105170-00008","article-title":"Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions.","volume":"154","author":"VanderWeele","year":"2011","journal-title":"Ann Intern Med"},{"issue":"10","key":"ioi250058r12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women\u2019s Health Initiative randomized trials.","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"ioi250058r13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/gme.0b013e3182014849","article-title":"Vasomotor symptoms and cardiovascular events in postmenopausal women.","volume":"18","author":"Szmuilowicz","year":"2011","journal-title":"Menopause"},{"issue":"8","key":"ioi250058r14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1001\/archinte.168.8.840","article-title":"Persistent hot flushes in older postmenopausal women.","volume":"168","author":"Huang","year":"2008","journal-title":"Arch Intern Med"},{"issue":"9","key":"ioi250058r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3128","article-title":"Menopausal hormone therapy use among postmenopausal women.","volume":"5","author":"Yang","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"5","key":"ioi250058r16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/GME.0000000000002335","article-title":"Use of menopausal hormone therapy beyond age 65 years and its effects on women\u2019s health outcomes by types, routes, and doses.","volume":"31","author":"Baik","year":"2024","journal-title":"Menopause"},{"issue":"6","key":"ioi250058r17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology"},{"issue":"6","key":"ioi250058r18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1055\/s-0034-1384625","article-title":"Reconciling the divergent findings from clinical trials and observational studies of menopausal hormone therapy for prevention of coronary heart disease.","volume":"32","author":"Rossouw","year":"2014","journal-title":"Semin Reprod Med"},{"issue":"6","key":"ioi250058r19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1161\/HYPERTENSIONAHA.107.106526","article-title":"Menopausal complaints are associated with cardiovascular risk factors.","volume":"51","author":"Gast","year":"2008","journal-title":"Hypertension"},{"issue":"12","key":"ioi250058r20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.108.776823","article-title":"Hot flashes and subclinical cardiovascular disease: findings from the Study of Women\u2019s Health Across the Nation Heart Study.","volume":"118","author":"Thurston","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"ioi250058r21","doi-asserted-by":"publisher","first-page":"898.e1","DOI":"10.1016\/j.ajog.2020.06.039","article-title":"Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.","volume":"223","author":"Zhu","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"ioi250058r22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/gme.0b013e3181cb49e9","article-title":"The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women.","volume":"17","author":"Edlefsen","year":"2010","journal-title":"Menopause"},{"issue":"5","key":"ioi250058r23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/jth.13993","article-title":"Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women.","volume":"16","author":"Harrington","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"7","key":"ioi250058r24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society.","volume":"29","author":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel","year":"2022","journal-title":"Menopause"},{"issue":"1","key":"ioi250058r25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG Practice Bulletin No. 141: management of menopausal symptoms.","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"11","key":"ioi250058r26","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline.","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"ioi250058r27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking menopausal hormone therapy: for whom, what, when, and how long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"issue":"10382","key":"ioi250058r28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"ioi250058r6","unstructured":"Women\u2019s Health Initiative. Protocols and study consents. Accessed August 13, 2025. https:\/\/www.whi.org\/protocols-and-study-consents"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2838720\/jamainternal_rossouw_2025_oi_250058_1765481698.83467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:19Z","timestamp":1765814419000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2838720"}},"subtitle":["A Secondary Analysis of the Women\u2019s Health Initiative Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.4510","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}